Page last updated: 2024-08-24

fluorodeoxyglucose f18 and olanzapine

fluorodeoxyglucose f18 has been researched along with olanzapine in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Desco, M; Gispert, JD; Martínez, R; Molina, V; Palomo, T; Pascau, J; Reig, S; Sanz, J	1
Eichhammer, P; Hajak, G; Landgrebe, M; Langguth, B; Marienhagen, J; Sand, P	1
Aronowitz, J; Bloom, R; Brand, J; Brickman, AM; Buchsbaum, MS; Goldstein, KE; Hazlett, EA; Haznedar, MM; Heath, D; Newmark, RE; Starson, M	1
Bleich, S; Frieling, H; Hilfiker-Kleiner, D; Kahl, KG; Kotsiari, A; Scherr, M; Stapel, B	1

Trials

1 trial(s) available for fluorodeoxyglucose f18 and olanzapine

Article	Year
Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. International clinical psychopharmacology, 2005, Volume: 20, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Olanzapine; Positron-Emission Tomography; Psychiatric Status Rating Scales; Radiopharmaceuticals; Schizophrenia; Severity of Illness Index; Treatment Outcome	2005

Article

Year

Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia.

International clinical psychopharmacology, 2005, Volume: 20, Issue:1

Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Olanzapine; Positron-Emission Tomography; Psychiatric Status Rating Scales; Radiopharmaceuticals; Schizophrenia; Severity of Illness Index; Treatment Outcome

2005

Other Studies

3 other study(ies) available for fluorodeoxyglucose f18 and olanzapine

Article	Year
Cerebellar and thalamic metabolic changes visualized by [18]-FDG-PET in olanzapine-induced acute akathisia. Neuro endocrinology letters, 2006, Volume: 27, Issue:6 Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Cerebellum; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Olanzapine; Positron-Emission Tomography; Radiopharmaceuticals; Schizophrenia; Thalamus	2006
FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophrenia research, 2007, Volume: 94, Issue:1-3 Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Female; Fluorodeoxyglucose F18; Frontal Lobe; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Occipital Lobe; Olanzapine; Positron-Emission Tomography; Psychotic Disorders; Radiopharmaceuticals; Temporal Lobe	2007
Olanzapine and aripiprazole differentially affect glucose uptake and energy metabolism in human mononuclear blood cells. Journal of psychiatric research, 2017, Volume: 88 Topics: AMP-Activated Protein Kinase Kinases; Antigens, CD; Antipsychotic Agents; Aripiprazole; Benzodiazepines; DNA Methylation; Dose-Response Relationship, Drug; Excitatory Amino Acid Transporter 2; Flow Cytometry; Fluorodeoxyglucose F18; Gene Expression Regulation; Glucose; Glucose Transporter Type 3; Glutamate Plasma Membrane Transport Proteins; Humans; Ketone Oxidoreductases; Leukocytes, Mononuclear; Olanzapine; Protein Kinases; RNA, Messenger; RNA, Ribosomal, 18S; Statistics, Nonparametric	2017